Redefining Heart Valve Replacement

Xeltis is a clinical-stage medical device company pioneering a restorative approach in heart valve therapy. RestoreX, Xeltis technology platform, is the world's first polymer-based technology designed to enable natural restoration of heart valve function, through a therapeutic approach called Endogenous Tissue Restoration (ETR).
Potentially addressing 100,000s patients / year Xeltis is currently investigating additional applications of its innovative approach to restore other heart valves and blood vessels.
Xeltis closed a €45 Million Series C Financing to advance aortic and pulmonary valve programs.

Xeltis is accelerating progression

Xeltis has been recognized as a breakthrough medtech start-up

XELTIS CEO, Laurent Grandidier